For patients with low-risk prostate cancer managed with active surveillance, obesity may increase risk of progression

the ONA take:

According to a new study published in the journal European Urology, researchers have found that obesity is linked with an increased risk of progression of low-risk prostate cancers in patients that are managed by active surveillance.

For the study, the researchers identified 565 men undergoing active surveillance for low-risk prostate cancer. The researchers found that during the median follow-up of 48 months, 168 men (30%) experienced pathologic progression and 172 men (30%) experienced therapeutic progression.

They did not find an association between obesity and risk of progression at the time of confirmatory biopsy, but beyond that, obesity was linked with an increased risk of pathologic progression (P = 0.007) and therapeutic progression (P = 0.007).

For every 5 unit increase in body mass index (BMI), the risk of pathologic progression increases (HR = 1.5, 95% CI: 1.1-2.1, P = 0.02). Similarly, the risk of therapeutic progression increases in the same manner (HR = 1.4, 95% CI: 1.0-1.9, P = 0.05).

Ultimately, the findings suggest that obesity is associated with a significantly elevated risk of prostate cancer progression after the confirmatory biopsy.

For patients with low-risk prostate cancer managed with active surveillance, obesity may increase risk of progression
Obesity linked with increased risk of progression of low-risk prostate cancers in active surveillance.
In this study, authors want to determine if obesity is associated with progression in men on active surveillance (AS) for low–risk prostate cancer (PCa). Obesity was associated with a significantly increased risk of progression beyond the confirmatory biopsy. This suggests an increased risk of long–term biologic progression rather than solely misclassification.
READ FULL ARTICLE From Mdlinx
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs